Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Essock-Burns
Emma
E
Department of Radiology and Biomedical Imaging, University of California-San Francisco, UCSF Mail Code 2532, Byers Hall Room #303, 1700 4th Street, San Francisco, CA 94158-0223, USA. emma.essock-burns@radiology.ucsf.edu
Lupo
Janine M
JM
Cha
Soonmee
S
Polley
Mei-Yin
MY
Butowski
Nicholas A
NA
Chang
Susan M
SM
Nelson
Sarah J
SJ
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D005909:Glioblastoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007211:Indoles / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D010477:Perfusion; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D007211:Indoles; D003606:Dacarbazine; C504878:enzastaurin; D000077204:Temozolomide